The majority of Moderna’s (MNRA) revenue comes from governments abroad — which are bracing are for an ongoing need for COVID-19 vaccines this year.
While the U.S. waits on funding and for the U.S. Food and Drug Administration (FDA) to decide on which virus strain to attack through boosters, Moderna and other vaccine companies are anticipating waning immunity to become a concern.
“This virus is not getting less infectious,” Moderna CEO Stéphane Bancel told Yahoo Finance. “As you see more and…
Source link